Kezar Life Sciences to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present a corporate update during two upcoming investor conferences. The details of the presentations are as follows:
Stifel 2019 Healthcare Conference
Presentation: Wednesday, November 20 at 10:20am EST
Presenter: Christopher Kirk, President and Chief Scientific Officer
Jefferies London Healthcare Conference
Presentation: Thursday, November 21, 2019 at 7:20am GMT
Presenter: John Fowler, Chief Executive Officer
The presentations will be webcast live and may be accessed at the “Events & Presentations” section of the Company’s website at . Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), dermatomyositis (DM), polymyositis (PM), autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Additionally, Kezar has nominated KZR-261 as its first clinical candidate for the treatment of cancer from its protein secretion program and is undergoing IND-enabling studies for the program. For more information, visit .
CONTACT:
Celia Economides
